Otamixaban

Revision as of 20:29, 4 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Jump to navigation Jump to search
Otamixaban
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H26N4O4
Molar mass446.498 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Otamixaban (INN) is an inhibitor of Factor Xa,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

See also

References

  1. Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. PMID 17979700.


Template:WikiDoc Sources